Literature DB >> 21997397

APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.

Natalia Papeta1, Krzysztof Kiryluk, Ami Patel, Roel Sterken, Nilgun Kacak, Holly J Snyder, Phil H Imus, Anand N Mhatre, Anil K Lawani, Bruce A Julian, Robert J Wyatt, Jan Novak, Christina M Wyatt, Michael J Ross, Jonathan A Winston, Mary E Klotman, David J Cohen, Gerald B Appel, Vivette D D'Agati, Paul E Klotman, Ali G Gharavi.   

Abstract

A chromosome 22q13 locus strongly associates with increased risk for idiopathic focal segmental glomerulosclerosis (FSGS), HIV-1-associated nephropathy (HIVAN), and hypertensive ESRD among individuals of African descent. Although initial studies implicated MYH9, more recent analyses localized the strongest association within the neighboring APOL1 gene. In this replication study, we examined the six top-most associated variants in APOL1 and MYH9 in an independent cohort of African Americans with various nephropathies (44 with FSGS, 21 with HIVAN, 32 with IgA nephropathy, and 74 healthy controls). All six variants associated with FSGS and HIVAN (additive ORs, 1.8 to 3.0; P values 3 × 10(-2) to 5 × 10(-5)) but not with IgA nephropathy. In conditional and haplotype analyses, two APOL1 haplotypes accounted for virtually all of the association with FSGS and HIVAN on chromosome 22q13 (haplotype P value = 5.6 × 10(-8)). To assess the role of MYH9 deficiency in nephropathy, we crossbred Myh9-haploinsufficient mice (Myh9(+/-)) with HIV-1 transgenic mice. Myh9(+/-) mice were healthy and did not demonstrate overt proteinuria or nephropathy, irrespective of the presence of the HIV-1 transgene. These data further support the strong association of genetic variants in APOL1 with susceptibility to FSGS and HIVAN among African Americans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997397      PMCID: PMC3231781          DOI: 10.1681/ASN.2011040434

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

Review 1.  Focal segmental glomerulosclerosis in African Americans.

Authors:  J Kevin Tucker
Journal:  Am J Med Sci       Date:  2002-02       Impact factor: 2.378

2.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

3.  Cumulative risk for developing end-stage renal disease in the US population.

Authors:  Bryce A Kiberd; Catherine M Clase
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

4.  Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy.

Authors:  B I Freedman; J M Soucie; S M Stone; S Pegram
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

5.  HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis.

Authors:  Yiqin Zuo; Taiji Matsusaka; Jianyong Zhong; Ji Ma; Li-jun Ma; Zaher Hanna; Paul Jolicoeur; Agnes B Fogo; Iekuni Ichikawa
Journal:  J Am Soc Nephrol       Date:  2006-09-20       Impact factor: 10.121

6.  Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes.

Authors:  J B Kopp; M E Klotman; S H Adler; L A Bruggeman; P Dickie; N J Marinos; M Eckhaus; J L Bryant; A L Notkins; P E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

7.  Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15.

Authors:  George W Nelson; Barry I Freedman; Donald W Bowden; Carl D Langefeld; Ping An; Pamela J Hicks; Meredith A Bostrom; Randall C Johnson; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2010-02-02       Impact factor: 6.150

8.  HIV-associated nephropathy in transgenic mice expressing HIV-1 genes.

Authors:  P Dickie; J Felser; M Eckhaus; J Bryant; J Silver; N Marinos; A L Notkins
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

Review 9.  HIV-associated nephropathy in the era of antiretroviral therapy.

Authors:  Christina M Wyatt; Paul E Klotman
Journal:  Am J Med       Date:  2007-06       Impact factor: 4.965

10.  Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice.

Authors:  Mary Anne Conti; Sharona Even-Ram; Chengyu Liu; Kenneth M Yamada; Robert S Adelstein
Journal:  J Biol Chem       Date:  2004-08-02       Impact factor: 5.157

View more
  49 in total

1.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

Review 2.  Biomarkers for incident CKD: a new framework for interpreting the literature.

Authors:  Michael G Shlipak; Erica C Day
Journal:  Nat Rev Nephrol       Date:  2013-06-11       Impact factor: 28.314

Review 3.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

4.  Exome-Based Rare-Variant Analyses in CKD.

Authors:  Sophia Cameron-Christie; Charles J Wolock; Emily Groopman; Slavé Petrovski; Sitharthan Kamalakaran; Gundula Povysil; Dimitrios Vitsios; Mengqi Zhang; Jan Fleckner; Ruth E March; Sahar Gelfman; Maddalena Marasa; Yifu Li; Simone Sanna-Cherchi; Krzysztof Kiryluk; Andrew S Allen; Bengt C Fellström; Carolina Haefliger; Adam Platt; David B Goldstein; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2019-05-13       Impact factor: 10.121

5.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

6.  Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Authors:  Amit C Achhra; Amanda Mocroft; Michael Ross; Lene Ryom-Nielson; Anchalee Avihingsanon; Elzbieta Bakowska; Waldo Belloso; Amanda Clarke; Hansjakob Furrer; Gregory M Lucas; Matti Ristola; Mohammed Rassool; Jonathan Ross; Charurut Somboonwit; Shweta Sharma; Christina Wyatt
Journal:  Int J Antimicrob Agents       Date:  2017-06-28       Impact factor: 5.283

7.  APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans.

Authors:  Alex N Kasembeli; Raquel Duarte; Michèle Ramsay; Pulane Mosiane; Caroline Dickens; Thérèse Dix-Peek; Sophie Limou; Efe Sezgin; George W Nelson; Agnes B Fogo; Stewart Goetsch; Jeffrey B Kopp; Cheryl A Winkler; Saraladevi Naicker
Journal:  J Am Soc Nephrol       Date:  2015-03-18       Impact factor: 10.121

Review 8.  Insights into kidney diseases from genome-wide association studies.

Authors:  Matthias Wuttke; Anna Köttgen
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

9.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

10.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.